It looks like a great buy-and-hold option.

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the

Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6,

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for po

AbbVie knows how to plan ahead.

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, ap

Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy&#3

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Stifel analyst Akash Tewari downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold and rai

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See

Pre-Market Stock Futures: Futures are trading higher this morning, but if you've ever heard the old

Mizuho analyst Joseph Catanzaro downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform to N

Deutsche Bank analyst David Hoang downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold a

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology

Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgrad

Citigroup analyst Geoff Meacham downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perf

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

UBS analyst Michael Yee downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral and rais

Wall Street analysts changed ratings for PRIM, ZION, and APGE. Check out analysts' views on thes

Nova Minerals Corp (ASX:NVA, NYSE-A:NVA, FRA:QM30) has completed its redomicile to the United States

Wedbush analyst David Nierengarten downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform t

G50 Corp Ltd (ASX:G50, OTCQB:GFYTF) has delivered a strong first result from its 2026 core drilling

Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF), the AIM-quoted and OTCQX-traded exploration and developmen

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the gold and uranium developer and investor, has bu

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquis

NEW YORK, June 22, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & As

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1 

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perf

Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold

BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintain

Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phas

Wedbush analyst David Nierengarten maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zum

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic roya

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.06) per share which beat the anal

Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:APGE) wit